Biogen Plans to Submit Final Design of Aduhelm Confirmatory Trial to FDA in March

Biogen Inc said on Thursday it was expecting to submit a final design for a post-marketing confirmatory study of its newly approved Alzheimer’s drug, Aduhelm, to the U.S. Food and Drug Administration in March, and begin screening of patients in May. Read More